Technology description:
Ivacaftor (VX-770) is a CF transmembrane conductance regulator agonist. It acts as a `potentiator’ increasing the activity of the defective CF transmembrane regulator (CFTR) protein. Ivacaftor is designed to restore the function of the mutated CFTR protein. In clinical trials, ivacaftor is administered orally at 150mg twice daily in addition to standard care.
